UK Medicines Information
Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial
Information type:
Randomised controlled trials
Source:
The Lancet Neurology
Specialities:
Neurological disorders
Summary
No benefit was seen in the use of simvastatin (40mg daily for upto 21 days) for long-term or short-term outcome in patients with aneurysmal subarachnoid haemorrhage (n=803). It is concluded these patients should not be treated routinely with simvastatin during acute stages.
UKMi comment
The following resource may also be of use:
Related links:
Comment – full text, access to subscribers